Soleno Therapeutics Files 8-K: Material Agreement & Other Events
Ticker: SLNO · Form: 8-K · Filed: 2024-05-07T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, corporate-filing, financials
Related Tickers: SLNO
TL;DR
SOLENO THERAPEUTICS (SLNO) FILED AN 8-K ON 5/2/24 DETAILING A MATERIAL AGREEMENT AND OTHER EVENTS.
AI Summary
On May 2, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed within the filing. The company also reported other events and filed financial statements and exhibits. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates significant corporate activity for Soleno Therapeutics, including a material agreement and the submission of financial information, which could impact investor understanding of the company's current status and future direction.
Risk Assessment
Risk Level: medium — Material definitive agreements and other events reported on an 8-K can signal significant business developments that may carry inherent risks or opportunities for the company.
Key Players & Entities
- SOLENO THERAPEUTICS, INC. (company) — Registrant
- May 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36593 (commission_file_number) — SEC File Number
- 77-0523891 (irs_number) — IRS Employer Identification Number
- 203 Redwood Shores Pkwy , Suite 500 Redwood City , CA 94065 (address) — Address of principal executive offices
- 650-213-8444 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement entered into by Soleno Therapeutics?
The filing states that Soleno Therapeutics, Inc. entered into a Material Definitive Agreement on May 2, 2024, but the specific details of this agreement are not provided in the excerpt.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 7, 2024, with the earliest event reported being May 2, 2024.
What is Soleno Therapeutics' state of incorporation and IRS Employer Identification Number?
Soleno Therapeutics, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 77-0523891.
What is the principal executive office address and phone number for Soleno Therapeutics?
The principal executive offices are located at 203 Redwood Shores Pkwy, Suite 500, Redwood City, CA 94065, and the phone number is (650) 213-8444.
What was Soleno Therapeutics' former company name?
Soleno Therapeutics, Inc.'s former company name was Capnia, Inc., with a date of name change on February 19, 2010.
Filing Stats: 922 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-05-07 17:28:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $46.00 — n Stock "), at a price to the public of $46.00 per share. Under the terms of the Under
- $129.3 million — mpany, are expected to be approximately $129.3 million. The shares of Common Stock in the Pu
Filing Documents
- d808535d8k.htm (8-K) — 30KB
- d808535dex11.htm (EX-1.1) — 202KB
- d808535dex51.htm (EX-5.1) — 9KB
- d808535dex991.htm (EX-99.1) — 8KB
- g808535g0506235139010.jpg (GRAPHIC) — 3KB
- g808535g0506235524329.jpg (GRAPHIC) — 3KB
- g808535g0506235524547.jpg (GRAPHIC) — 1KB
- 0001193125-24-133322.txt ( ) — 446KB
- slno-20240502.xsd (EX-101.SCH) — 3KB
- slno-20240502_lab.xml (EX-101.LAB) — 18KB
- slno-20240502_pre.xml (EX-101.PRE) — 11KB
- d808535d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated as of May 2, 2024, by and among Soleno Therapeutics, Inc., Piper Sandler & Co. and Guggenheim Securities, LLC, as representatives of the underwriters named therein. 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto) 99.1 Press release issued by Soleno Therapeutics, Inc. dated May 2, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: May 7, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer